Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sierra Oncology Inc (SRRA)

Sierra Oncology Inc (SRRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Sierra Oncology Inc 1820 Gateway Drive Suite 110 San Mateo CA 94404 USA

www.sierraoncology.com P: 650-376-8679

Description:

Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central regulator of the DNA Damage Response network. SRA141 is an orally available small molecule inhibitor of cell division cycle 7kinase. Sierra Oncology, Inc., formerly known as ProNAi Therapeutics, Inc., is headquatered in Vancouver, Canada.

Key Statistics

Overview:

Market Capitalization, $K 1,342,801
Enterprise Value, $K 1,342,532
Shares Outstanding, K 24,419
Annual Sales, $ 0 K
Annual Net Income, $ -94,660 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -27,930 K
60-Month Beta 0.01
% of Insider Shareholders 67.68%
% of Institutional Shareholders 99.30%
Float, K 7,892
% Float 32.32%
Short Volume Ratio 0.26

Growth:

1-Year Return 182.43%
3-Year Return 143.19%
5-Year Return 17.50%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 88.70%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.33 on 05/06/22
Latest Earnings Date 08/04/22
Earnings Per Share ttm -6.77
EPS Growth vs. Prev Qtr 20.36%
EPS Growth vs. Prev Year 22.22%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-40 on 01/23/20

SRRA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -76.49%
Return-on-Assets % -69.85%
Profit Margin % 0.00%
Debt/Equity 0.02
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 5.13
Book Value/Share 10.71
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar